Novo Nordisk Introduces Groundbreaking Weight Loss Pill in U.S.
American patients have been introduced to a revolutionary shift in obesity treatment with the launch of the first-ever GLP-1 pill for weight loss. Novo Nordisk officially launched its Wegovy pill on January 5, 2026. This daily oral medication is now accessible at over 70,000 U.S. pharmacies, including notable chains like CVS and Costco, as well as through select telehealth providers.
The groundbreaking drug offers unprecedented accessibility with cash prices ranging from $149 to $299 per month, depending on the dosage. This pricing is among the lowest on the market for GLP-1 medications. The Wegovy pill works by mimicking the gut hormone GLP-1 to suppress appetite. Clinical trials have shown that patients lost up to 16.6% of their weight on average after 64 weeks of use.
This launch gives Novo Nordisk a significant head start in what analysts predict could be a $22 billion oral weight loss drug market by 2030. Industry experts note that pills represent the next major battleground in the booming GLP-1 space. Competitor Eli Lilly is expected to seek FDA approval for its own weight loss pill later this year.
Source: CNBC